# Evommune

**Canonical:** https://apis.io/providers/evommune/  
**Website:** https://www.evommune.com/  
**APIs profiled:** 0

Evommune, Inc. (Nasdaq: EVMN) is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California, discovering and developing therapies that target the key drivers of chronic inflammatory disease. Founded in 2020 by the team behind Dermira, the company applies a human tissue-based translational approach to immunology and is advancing a clinical pipeline that includes EVO756, an oral small-molecule MRGPRX2 antagonist in Phase 2b development for chronic spontaneous urticaria and migraine prophylaxis, and an IL-18 binding protein fusion program licensed from AprilBio. Evommune publishes no developer program, no public API and no machine-readable API contract; its public web presence is a WordPress marketing site plus a hosted investor-relations portal.

## Kin Score — 11.1 / 100 (minimal)

Scored 2026-08-17 under rubric 0.11.0. Trend: flat (+0.0 from 11.1).

| Facet | Score |
|---|---|
| Discoverability | 57.4 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 21.1 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Security (1)

- **Evommune Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Biotechnology, Pharmaceuticals, Life Sciences, Immunology, Drug Development, Clinical Trials, Healthcare

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/evommune/). Scores are computed from the provider's own public artifacts under a published rubric.